Cargando…

Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer

This study aimed to first elucidate prostate-specific antigen (PSA) kinetics in prostate cancer patients treated with carbon ion radiotherapy (CIRT). From 2010 to 2015, 131 patients with prostate adenocarcinoma treated with CIRT (57.6 Gy relative biological effectiveness (RBE) in 16 fractions) alone...

Descripción completa

Detalles Bibliográficos
Autores principales: Darwis, Narisa Dewi Maulany, Oike, Takahiro, Kawamura, Hidemasa, Kawahara, Masahiro, Kubo, Nobuteru, Sato, Hiro, Miyasaka, Yuhei, Katoh, Hiroyuki, Ishikawa, Hitoshi, Matsui, Hiroshi, Miyazawa, Yoshiyuki, Ito, Kazuto, Suzuki, Kazuhiro, Gondhowiardjo, Soehartati, Nakano, Takashi, Ohno, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139713/
https://www.ncbi.nlm.nih.gov/pubmed/32143495
http://dx.doi.org/10.3390/cancers12030589
_version_ 1783518829685506048
author Darwis, Narisa Dewi Maulany
Oike, Takahiro
Kawamura, Hidemasa
Kawahara, Masahiro
Kubo, Nobuteru
Sato, Hiro
Miyasaka, Yuhei
Katoh, Hiroyuki
Ishikawa, Hitoshi
Matsui, Hiroshi
Miyazawa, Yoshiyuki
Ito, Kazuto
Suzuki, Kazuhiro
Gondhowiardjo, Soehartati
Nakano, Takashi
Ohno, Tatsuya
author_facet Darwis, Narisa Dewi Maulany
Oike, Takahiro
Kawamura, Hidemasa
Kawahara, Masahiro
Kubo, Nobuteru
Sato, Hiro
Miyasaka, Yuhei
Katoh, Hiroyuki
Ishikawa, Hitoshi
Matsui, Hiroshi
Miyazawa, Yoshiyuki
Ito, Kazuto
Suzuki, Kazuhiro
Gondhowiardjo, Soehartati
Nakano, Takashi
Ohno, Tatsuya
author_sort Darwis, Narisa Dewi Maulany
collection PubMed
description This study aimed to first elucidate prostate-specific antigen (PSA) kinetics in prostate cancer patients treated with carbon ion radiotherapy (CIRT). From 2010 to 2015, 131 patients with prostate adenocarcinoma treated with CIRT (57.6 Gy relative biological effectiveness (RBE) in 16 fractions) alone were recruited. PSA was measured at 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months post-CIRT. PSA bounce was defined as PSA increase over a cutoff followed by spontaneous decrease to or below the pre-bounce nadir. PSA failure was determined using the Phoenix criteria (nadir + 2.0 ng/mL). As a result, non-failure-associated temporary increase in PSA exhibited two distinct patterns, namely a classical bounce and a surge at one month. PSA bounce of ≥0.2 ng/mL was observed in 55.7% of the patients. Bounce amplitude was <2.0 ng/mL in 97.6% of cases. Bounce occurred significantly earlier than PSA failure. Younger age was a significant predictor of bounce occurrence. Bounce positivity was a significant predictor of favorable 5-year PSA failure-free survival. Meanwhile, a PSA surge of ≥0.2 ng/mL was observed in 67.9% of patients. Surge amplitude was significantly larger than bounce amplitude. Larger prostate volume was a significant predictor of PSA surge occurrence. PSA surge positivity did not significantly predict PSA failure. In summary, PSA bounce was distinguishable from PSA failure with regard to timing of occurrence and amplitude (earlier and lower for bounce, respectively). These data are useful for post-CIRT surveillance of prostate cancer patients.
format Online
Article
Text
id pubmed-7139713
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71397132020-04-10 Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer Darwis, Narisa Dewi Maulany Oike, Takahiro Kawamura, Hidemasa Kawahara, Masahiro Kubo, Nobuteru Sato, Hiro Miyasaka, Yuhei Katoh, Hiroyuki Ishikawa, Hitoshi Matsui, Hiroshi Miyazawa, Yoshiyuki Ito, Kazuto Suzuki, Kazuhiro Gondhowiardjo, Soehartati Nakano, Takashi Ohno, Tatsuya Cancers (Basel) Article This study aimed to first elucidate prostate-specific antigen (PSA) kinetics in prostate cancer patients treated with carbon ion radiotherapy (CIRT). From 2010 to 2015, 131 patients with prostate adenocarcinoma treated with CIRT (57.6 Gy relative biological effectiveness (RBE) in 16 fractions) alone were recruited. PSA was measured at 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, and 60 months post-CIRT. PSA bounce was defined as PSA increase over a cutoff followed by spontaneous decrease to or below the pre-bounce nadir. PSA failure was determined using the Phoenix criteria (nadir + 2.0 ng/mL). As a result, non-failure-associated temporary increase in PSA exhibited two distinct patterns, namely a classical bounce and a surge at one month. PSA bounce of ≥0.2 ng/mL was observed in 55.7% of the patients. Bounce amplitude was <2.0 ng/mL in 97.6% of cases. Bounce occurred significantly earlier than PSA failure. Younger age was a significant predictor of bounce occurrence. Bounce positivity was a significant predictor of favorable 5-year PSA failure-free survival. Meanwhile, a PSA surge of ≥0.2 ng/mL was observed in 67.9% of patients. Surge amplitude was significantly larger than bounce amplitude. Larger prostate volume was a significant predictor of PSA surge occurrence. PSA surge positivity did not significantly predict PSA failure. In summary, PSA bounce was distinguishable from PSA failure with regard to timing of occurrence and amplitude (earlier and lower for bounce, respectively). These data are useful for post-CIRT surveillance of prostate cancer patients. MDPI 2020-03-04 /pmc/articles/PMC7139713/ /pubmed/32143495 http://dx.doi.org/10.3390/cancers12030589 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Darwis, Narisa Dewi Maulany
Oike, Takahiro
Kawamura, Hidemasa
Kawahara, Masahiro
Kubo, Nobuteru
Sato, Hiro
Miyasaka, Yuhei
Katoh, Hiroyuki
Ishikawa, Hitoshi
Matsui, Hiroshi
Miyazawa, Yoshiyuki
Ito, Kazuto
Suzuki, Kazuhiro
Gondhowiardjo, Soehartati
Nakano, Takashi
Ohno, Tatsuya
Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
title Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
title_full Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
title_fullStr Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
title_full_unstemmed Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
title_short Kinetics of Prostate-Specific Antigen after Carbon Ion Radiotherapy for Prostate Cancer
title_sort kinetics of prostate-specific antigen after carbon ion radiotherapy for prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139713/
https://www.ncbi.nlm.nih.gov/pubmed/32143495
http://dx.doi.org/10.3390/cancers12030589
work_keys_str_mv AT darwisnarisadewimaulany kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT oiketakahiro kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT kawamurahidemasa kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT kawaharamasahiro kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT kubonobuteru kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT satohiro kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT miyasakayuhei kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT katohhiroyuki kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT ishikawahitoshi kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT matsuihiroshi kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT miyazawayoshiyuki kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT itokazuto kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT suzukikazuhiro kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT gondhowiardjosoehartati kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT nakanotakashi kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer
AT ohnotatsuya kineticsofprostatespecificantigenaftercarbonionradiotherapyforprostatecancer